哈里斯在 CNN 活动中失误

(SeaPRwire) -   美国大选临近,这位民主党人无法“完成交易”来赢得友好的选民。 副总统卡玛拉·哈里斯在 CNN 组织的一场选民大会上,难以解释她对美国的计划,对简单的问题给出含糊其辞的答案,并更愿意攻击她的对手唐纳德·特朗普。 民主党人在 7 月提名哈里斯,此前他们施压总统乔·拜登退出竞选。此后,她一直试图将自己塑造为变革的代言人,尽管拜登一再表示,她从第一天起就参与了现任政府的所有政策。 “已经做了很多事情,但还有更多事情需要做。我正在指出那些需要做但还没有做的事情,”哈里斯周三在接受 CNN 的安德森·库珀采访时说,当被问及自 2021 年以来,她目前的政策理念中为什么没有一项得到实施。 在活动后的讨论中,共和党评论员、前特朗普竞选助手大卫·厄本称之为“语无伦次”。他还说,共和党会很乐意再支付一小时的费用,只为让哈里斯继续说下去。 X 上的“特朗普战室”竞选账号热切地分享了这场大会的片段,在这些片段中,哈里斯甚至无法回答最简单的“抛球”问题。例如,库珀向哈里斯抛出一个引导性的“软球”问题,暗示她在三个以前有争议且不受欢迎的立场上的“转变”,她本应该简单地回答“是”。然而,这位民主党人却开始谈论她的计划的细节。 在另一个在网上疯传的对话中,库珀提醒哈里斯,她曾将边境墙称为“愚蠢、无用、中世纪的虚荣项目”,但她却投票赞成拨款 6.5 亿美元来完成它的建造。 “让我们谈谈唐纳德·特朗普吧,”哈里斯笑着说。她最后声称,她不同意特朗普建造边境墙的方式,而不是反对边境墙本身。 “‘特朗普很糟糕’并不是能让她当选的口号,”厄本后来指出。 “我认为,她更多地关注唐纳德·特朗普,而不是她自己作为总统会做什么的具体细节,”另一位 CNN 主持人杰克·塔珀说。 “如果她的目标是达成协议,他们不确定她是否做到了,” CNN 的黛娜·巴什说,她在 6 月主持了拜登与特朗普的辩论,她说她从一些民主党人那里听到了这种说法。巴什补充说,虽然选民们可能更好地了解了哈里斯是谁,但他们不确定她会做什么。“关于她的立法优先事项的问题,说一个?没有一个。” 无论问题是关于移民还是食品价格,哈里斯总是回到她在旧金山和加州检察官的经历。她还承认,她将实施价格管制,“改革”美国最高法院,因为她不同意其中一些裁决,并“在最富有的人缴税方面实现公平”,但没有解释这到底意味着什么。 本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。

域名注册热潮:ICANN 认证如何推动域名行业前所未有的增长

(SeaPRwire) -   分析自 2020 年以来域名注册量的激增,以及 ICANN 认证在促进充满活力的数字经济中发挥的关键作用。加利福尼亚州戴利城 2024 年 10 月 24 日 - 2020 年后的时代不可避免地改变了许多行业,但近年来,域名注册行业所经历的非凡增长是罕见的。随着企业在 2020 年的不确定时期争相建立在线业务,域名注册量激增,达到前所未有的水平。在这个蓬勃发展的市场核心是 ICANN(互联网名称与数字地址分配机构)认证所发挥的关键作用,这种认证已成为注册商在竞争激烈的市场中蓬勃发展的必备条件。 全球约有 6.285 亿个已注册域名,该市场不仅规模庞大,而且越来越多地被拥有 ICANN 认证的企业所主导。Verisign 的数据显示,到 2021 年底,已注册域名数量达到 4.384 亿个,与前一年相比惊人地增长了 117%。这种上升趋势强调了公司在数字战略方面发生的变化,而这种变化是由 2020 年的不确定时期所迫使的转向在线业务模式所推动的。 域名注册量的惊人增长统计数据揭示了域名注册量的显著轨迹。随着企业转向电子商务和在线服务,对唯一域名名称的需求变得更加突出。到 2020 年底,已注册域名数量达到 2.016 亿个,高于 2019 年的 1.6596 亿个。最受欢迎的域名扩展名仍然是 .com,占总注册量的 37%。但是,域名扩展名的多样性仍在不断增长,反映出不断扩大的数字市场。新的 gTLD,例如 .online、.club、.shop 等,为客户提供了更广泛的选择,如果他们想要的 .com 不可用或已被注册,他们可以选择这些扩展名。 作为 和行业专家, 指出,“疫情后,随着企业转向线上,对域名名称的需求激增,促使许多域名经销商寻求 ICANN 认证以提升其合法性并扩大其产品和服务。” Venkatesh 的公司 在过去 4 年中帮助超过 25 家公司获得了 ICANN 认证。 ICANN 认证的重要性对于域名注册商而言,ICANN 认证不仅仅是一项荣誉称号;它是可持续增长和竞争优势的重要组成部分。获得这种认证的注册商可以直接访问注册机构,消除中间商,使他们能够制定可以增强其市场地位的定价结构。 “对 ICANN 认证的需求比以往任何时候都更加清晰,” 指出。“注册商认识到获得认证不仅仅是为了利润;而是为了独占性。如今,寻求 ICANN 认证的不仅仅是域名注册公司;SEO 公司和网络托管提供商也加入了这一行列。这种认证为他们的业务增加了重要价值,使他们能够提供全面的服务并增强他们在竞争市场中的信誉。” ICANN 认证的优势可以归类为几个关键利益: 控制和灵活性:经认证的注册商可以直接管理运营,从而提高适应性。 信誉和信任:获得 ICANN 认证可以增强信誉,因为客户更有可能信任符合严格行业标准的注册商。 更高的利润率:通过绕过中间商,经认证的注册商可以降低成本,从而提高盈利能力。 市场扩展:认证打开了通往新机会的大门,并能够提供更广泛的 TLD(顶级域名)。 影响故事 近年来,包括乌兹别克斯坦、阿尔巴尼亚和开曼群岛在内的几个国家/地区迎来了首批获得 ICANN 认证的域名注册商。这一里程碑标志着该行业取得了重大进步。通过有效地利用其认证,这些注册商增强了客户信任并使其服务多样化,推动了各自市场的发展。 域名注册的未来随着域名名称行业的不断发展,对 的需求预计将加剧。注册商开始认识到,这种认证不仅仅是为了合规,而且对于开拓新的收入来源和巩固他们在行业中的地位也至关重要。 行业观察人士预计,随着越来越多的企业寻求建立或增强其在线业务,对经认证的注册商的需求只会增加。“我们正在见证行业的变化,” Venkatesh 断言。“对认证赋予注册商权力的认识正在变得普遍。” 结论域名注册市场正在经历着令人印象深刻的上升轨迹,这得益于数字革命,并由 ICANN 认证推动。随着企业寻求建立或增强其数字业务,认证提供的优势将继续成为推动该行业发展的主要力量。2020 年后的域名注册量激增不仅仅是一个统计异常;它代表着企业与其客户互动以及适应日益数字化世界的方式的根本转变。随着格局的变化,那些接受 ICANN 认证的人将能够在这新时代的域名行业中获得收益。媒体联系方式Dotup ICANN Accreditation Consultancy+91 98949 06326465 Verducci Dr 来源:Dotup ICANN Accreditation Consultancy本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。

Kryterion Strengthens Japan Operations to Enhance Client Service Capabilities

TOKYO, October 25, 2025 - (ACN Newswire via SeaPRwire.com) - Kryterion Inc. announces the expansion of its Japan operations in an exciting move that will extend its software as a service (SaaS) certification and assessment software services for new and existing clients headquartered in Japan, reinforcing its commitment to client service excellence."Kryterion is set to be a premier provider of Japanese-language test delivery and locally staffed support services in Japan and for the international community," says William Dorman, Kryterion Chairman. "Simultaneously, we will introduce our highly secure, computer-based assessment management services to Japanese organizations serving the dynamic Japanese marketplace and the wider international community. Kryterion has a proven track record in transitioning from paper-based testing to computer-based testing and from onsite computer-based testing to secure, internet-based, proctored testing."Kryterion is a leading SaaS digital test development and test delivery provider in international markets, with approximately 1000 test center affiliates. It introduced secure, online proctored (OLP) exam delivery with a lockdown browser in 2007 and today provides global assessment services support, including Japanese language testing in Japan. Kryterion a subsidiary of the Drake International Group, which, through its subsidiaries, possesses a presence in 13 countries, including Japan, Korea, Taiwan, Hong Kong, Singapore, the Philippines, New Zealand, and Australia. Currently, Drake International's largest subsidiary in Japan is Drake Business Services Asia (DBSA). Led by CEO Grant Mackenzie, the company has been active in Japan since 2017. DBSA is a leading managed services provider, offering complete outsourced management of non-core support functions to deliver measurable cost reductions and efficiency improvements.According to Dorman, "The success of Drake Business Services Asia in Japan and across the region, coupled with growing acceptance of Kryterion's highly secure digital test development and test delivery services - especially in Japan's high technology sector - have prompted our decision to expand Kryterion's current presence in Japan dramatically."Contact Information:Yoshinori Nambo, Japan Sales Manager, Kryterion, Inc.Email: ynambo@KryterionOnline.com Website: www.Kryterion.com  Buzz Walker, Chief Revenue Officer,  Kryterion, Inc.Email: bwalker@KryterionOnline.com Website: www.Kryterion.com  Copyright 2024 ACN Newswire via SeaPRwire.com.

MHI-MME Licenses Manufacturing and Sale of MET Turbochargers to Leading Chinese Marine Machinery Manufacturer

TOKYO, Oct 25, 2024 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Heavy Industries Marine Machinery and Equipment Co., Ltd (MHI-MME), a part of Mitsubishi Heavy Industries (MHI) Group, has concluded a licensing agreement with Jiangsu Masada Heavy Industries Co, Ltd. (Jiangsu Masada), a privately owned marine machinery manufacturer in China, for the manufacture and sale of MET Turbochargers, its exhaust gas turbine type turbochargers for two-stroke marine engines.Signing CeremonyWith the conclusion of this agreement, Jiangsu Masada plans to start manufacturing MET Turbochargers in 2025, focusing principally on assembly, and gradually expanding to full-scale production including processes other than assembly. MHI-MME's aim with this licensing agreement is to further penetrate the Chinese market with high-quality products and services.Jiangsu Masada has a long relationship with MHI Group, and has previously concluded licensing agreements for deck cranes in 2008, and steering gears and deck machinery in 2012. At present, Jiangsu Masada is a leading manufacturer of marine machinery, boasting the largest share in the Chinese market for deck cranes, deck machinery, and steering gears.MHI-MME developed the world's first non-water cooled turbocharger, the forerunner of the MET series, in 1965. High-efficiency, high-capacity models have since been added to the lineup, and today MET Turbochargers are one of the global standards for exhaust gas turbine types. Total cumulative production volume of MET Turbochargers has now reached 45,000 units, accounting for more than 40%(Note) of the global market (in fiscal 2023) for units used in marine two-stroke engines.Going forward, MHI-MME will continue to maintain and develop a positive cooperative relationship with Jiangsu Masada, and further proactively develop and market MHI brand marine machinery.About MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com. Copyright 2024 JCN Newswire via SeaPRwire.com.

EduEdge Introduces Formula-Style Method, Changing English Mastery for Struggling Students

With a structured, step-by-step approach, EduEdge equips students not just for exams, but for lifelong mastery of English, giving parents a proven solution for their children's learning challenges Singapore - October 25, 2024 - (SeaPRwire) - EduEdge is proud to announce its Formula-Style method, designed to transform the way struggling students master English. Despite English being Singapore's first language, many students struggle with deeper aspects of the language, such as comprehension, written expression and critical thinking. This proficiency gap affects not only their English grades but also their performance in other subjects. Research highlights a strong link between English language proficiency and academic achievement in areas like Maths and Science, underscoring the importance of mastering English for well-rounded academic success. Traditional teaching methods often fall short of helping students achieve true language mastery. As English is the most widely spoken language globally, this lack of holistic proficiency concerns parents who want their children to excel, not just in exams but in life. EduEdge addresses this challenge through a revolutionary approach to English education. Pioneered by founder Edwin Edangelus Cheng, EduEdge developed the groundbreaking Formula-Style method, designed to take the guesswork out of English learning. Backed by years of educational research, this structured approach goes beyond exam preparation by equipping students with the critical language skills and deep understanding necessary for lifelong success. By breaking down complex language concepts into easy-to-apply formulas, EduEdge empowers students to excel academically while mastering the communication skills essential for future professional achievements. Edwin Edangelus Cheng's personal journey resonates with many parents and students. "I once was like your child," Edwin shares, recalling his struggles with English as a student from a Chinese-speaking family. His experience and years as a public school teacher, where he taught both English and Physics, inspired him to find structured methods for language learning. "I saw how students approached learning English," Edwin explains. "They often rely on intuition without the structure or proper articulation needed for true mastery. In Physics, we see results quickly because of its formula and steps. I wondered, could the same formula-style approach work for English?" This question led to the development of EduEdge's Formula-Style method, offering a more structured and methodical way to teach and learn English. What makes the Formula-Style method different is its ability to break down English learning into easy-to-apply and easy-to-remember formulas, similar to Maths and Science. This system, known as the Total English Mastery System (TEMS), helps students learn English in a faster, smarter and more effective way. Over the past 10 years, TEMS has helped more than 3,500 students from over 150 schools across Singapore improve by at least two grades, with many achieving high Bs and As in English and General Paper (GP) exams. Students who started with borderline or failing grades found success by mastering six core language skills—Vocabulary, Grammar, Reading, Writing, Listening and Speaking. The impact of the Formula-Style method is shown in the stories of students who have experienced notable success. One such example is Angela Ray Oh, who, like many others, struggled with English during secondary school and was stuck at a C6 grade despite her determination. Her breakthrough came in Sec 4 when her mum enrolled her in EduEdge. After learning structured techniques, Angela's approach to English transformed, leading her to score an A2 for her O-Levels. The benefits of these techniques extended beyond secondary school. While studying at Nanyang Technological University (NTU), Angela was awarded the Lee Kuan Yew (LKY) STEP Award, a highly competitive scholarship. The application process required writing two essays within 48 hours. Drawing on the writing techniques and critical thinking skills she gained at EduEdge, Angela crafted her submissions with confidence and aced both essays and the interview, demonstrating how EduEdge's method equips students for real-world success. This success is no coincidence. EduEdge's Formula-Style method is powerful, but its true impact is realised through the exceptional educators who bring it to life. The highly qualified and passionate teachers at EduEdge are rigorously selected, ensuring that the method is delivered to its full potential. This combination of structured techniques and top-tier teaching creates a transformative learning experience that drives students' success. Every journey at EduEdge begins with a Diagnostic Consultation Assessment (DCA) involving both parents and students. This personalised session provides a clear and quantifiable understanding of the child's current abilities and identifies specific areas that need improvement. Many parents believe misconceptions like, "My child speaks English, but their test results aren't great," or "My child reads a lot, but the results aren't improving." The DCA dispels these misconceptions by pinpointing underlying issues in comprehension, writing or critical thinking. This tailored approach allows EduEdge to develop a plan for effective improvement, ensuring more conducive learning. Parental involvement is a key aspect of the EduEdge approach. Regular feedback is provided via email, based on detailed marking of the child's submitted work. This ensures parents stay up to date on their child's progress. Post-lesson consultations are also available to address any specific concerns. Committed to continuous innovation, EduEdge keeps refining its methods to ensure students receive quality education not just for exams but for lifelong success. As part of its forward-thinking approach, EduEdge is exploring the use of AI and cutting-edge technology to personalise learning for every student further and extend educational support beyond the classroom. These tools will help create a more adaptive learning environment that tracks progress, identifies areas for improvement in real time and provides tailored resources. Additionally, EduEdge is expanding its reach with care, ensuring that high teaching quality is never diluted while maintaining accessibility for students and parents. With existing branches in Serangoon and Bukit Timah, EduEdge is set to open a new branch in Marine Parade, further increasing accessibility across Singapore while upholding the high standards that has made it one of the country's leading English tuition specialists. Experience the EduEdge difference today. Book a complimentary 60-minute DCA using the coupon code ELSUCCESS. Give your child, aged 10 to 18 (or Primary 4 to Junior College 2), the personalised support they need to improve their English skills and excel academically. Media Contact Edwin Edangelus Cheng EduEdge English & GP Specialists Website: https://eduedge.com.sg/DCA/ WhatsApp: https://wa.link/q77cvq   The article is provided by a third-party content provider. SeaPRwire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Sectors: Top Story, Corporate News SeaPRwire provides real time press release distribution for companies and organizations to 6,500+ media outlets & 3.5 million professional desktops in 90 regions. It distributes press releases in different languages, including: IndonesiaFolk, IndoNewswire, SEATribune, IDNewsZone, LiveBerita, DailyBerita, TaiwanPR, SinchewBusiness, AsiaEase, BuzzHongKong, SingapuraNow, TIHongKong, TaipeiCool, TWZip, AsiaFeatured, dePresseNow, THNewson, KULPR, VNFeatured, MENAEntry, HunaTimes, DubaiLite, ArabicDir, BeritaDaring, TekanAsia, JamKopi ...

LIGHTS and SOUNDS at the JBL Rewind Revolution Roadshow

KUALA LUMPUR, MALAYSIA, Oct 24, 2024 - (ACN Newswire via SeaPRwire.com) - JBL®, the renowned lifestyle audio brand under Harman International, celebrated the launch of the “JBL Rewind Revolution Roadshow” today, bringing the party to life with its portable JBL PartyBox speakers and JBL PartyLight. Using AuracastTM technology, JBL PartyBox and JBL PartyLight sync seamlessly with each other and the music, creating a next-level sensory experience.JBL PartyLight BeamJBL PartyLight StickFor a more personal experience, the flagship True Wireless Stereo (TWS) earbuds, JBL Tour Pro 3, which is the first TWS with Auracast by JBL, rocketed onto the roadshow, with a Smart Charging Case with feature rich touchscreen, Real-Time True Adaptive Noise Cancelling and new audio transmitter for in-flight. The JBL Rewind Revolution Roadshow runs from 21-27 October at Mid Valley Mega Mall, East Entrance Atrium.The latest products designed to elevate your get-together or events are the JBL PartyLight Beam and JBL PartyLight Stick. While both add dynamic lighting synced to the best of the music, the JBL PartyLight Beam is a compact unit ideal for kinetic lighting effect. The JBL PartyLight Stick stands around one meter tall, is great for adding 330º room-filling mood enhancing features to your playlist. Both products use AuracastTM technology to connect effortlessly to a JBL PartyBox with a simple push of a button on each device. Control the speed, colours and patterns from the JBL PartyBox app. The built-in microphone with music detection algorithm, allows JBL PartyLight Beam and JBL PartyLight Stick to sync to the music playing in the room.The roadshow also featured JBL Partybox Club 120 and JBL PartyBox Stage 320, showcasing impressive JBL Pro Sound, sub-grille lights, and battery-powered performance. Whether it is dance or R&B, JBL PartyBox speakers deliver JBL’s renowned high-quality sound. These portable speakers come with a plethora of controls and features from the product-topping control panel, built-in handle, replaceable battery, IPX4 splashproof resistance, microphone and guitar inputs, plus Bluetooth to connect to your favourite music app from your preferred device.Mr. Henry Yap, Managing Director of Global Best United (M) Sdn Bhd said, “You can now party outside the box and enter a whole new soundscape with JBL PartyLight Beam and JBL PartyLight Stick as your essential elements for creating unforgettable parties. Whether it’s a holiday party or an intimate evening, synchronised music and lights can set the perfect mood.”“While JBL PartyBox Club 120 and JBL PartyBox Stage 320 can be paired with JBL PartyLight Stick and JBL PartyLight Beam, it is also very versatile and sturdy for use outdoor and indoor. Both comes with powerful JBL Pro Sound, futuristic lightshow, and splash proof, you can use it as a speaker or add a microphone, you can take your karaoke parties and outdoor celebrations to the next level”, Henry added.Mr. Mitchell Wong, Business Development Manager for JBL Malaysia said, “The technological advancements of the JBL Tour Pro 3 offer a feature-rich, fully customisable system. The JBL Tour Pro 3 is the flagship TWS earbud from JBL, with the latest audio technology like JBL Spatial 360 with Head Tracking, True Adaptive Noise Cancellation 2.0 and the first dual driver earbud.”The dual-driver design in the JBL Tour Pro 3 enhances audio performance, reducing distortion and improving sound clarity. The True Adaptive Noise Cancellation 2.0 system monitors and recalibrates over 50,000 times per second, recalibrating to adapt to environmental changes and compensating for sound leakage. The earbuds also ship with five additional ear-tips options - four silicon and one foam - for enhanced comfort and fit. Available in two colours, black and latte, the JBL Tour Pro 3’s smart case screen can be personalised with a photo, wallpaper and supports 13 languages.Availability. All featured JBL® products are available for purchase at Lazada, Shopee, and all leading retailers:ALL IT, Viewnet, Urban Republic, Thundermatch, Vivid Concepts, PC Image, SY Electric, THT, One Living, Harvey Norman, AES, Central Electronics, SS Audio, Brightstar Computers, Style Laser and EKS.Find out more about the JBL Products at https://www.jblonlinestore.com.my.Hi-Res Images. Please download hi-res product and lifestyle images from this link.For media information, kindly contact:Triven Marketing Group, for JBL® MalaysiaJazzmin WanEmail: j.wan@swanconsultancy.biz Copyright 2024 ACN Newswire via SeaPRwire.com.

Governments, Law Enforcement, and Industry Leaders to Convene at Global Anti-Scam Summit Americas 2024 in Washington D.C.

Washington, D.C., Oct 25, 2024 - (ACN Newswire via SeaPRwire.com) - Online scams wreak havoc across the Americas and globally, causing significant financial and emotional damage. The Global Anti-Scam Summit (GASS) Americas 2024, organized by the Global Anti-Scam Alliance (GASA) and hosted by Amazon.com, Inc., aims to combat these growing threats. The summit will feature over 30 hours of presentations, workshops, and interactive sessions across ten critical tracks, all focused on developing a global defense strategy to protect consumers and inform regulation.The summit will empower experts to take decisive action by focusing on the impact on victims, highlighting global scam statistics, explaining emerging scam tactics, and fostering international cooperation. The aim is to provide a roadmap for regulatory bodies to drive meaningful change.With $1.026 billion in global scam losses in 2023, this event seeks to mitigate further damage in 2024 and beyond.Day 1 will address the human and policy aspects of scams:Victim Impact: Led by AARP, this session delves into the emotional and financial toll on victims and their communities.Policy: The Aspen Institute will explore regulatory gaps and legislative solutions, sharing best practices from around the world.Law Enforcement: Chaired by UNODC, this session focuses on the collaboration between local and international agencies to disrupt scam networks.Data & Signal Sharing: GASA and DNS Research Federation will unveil plans for an international cybercrime exchange to reduce cybercrime by 50% in 10 years.Bank Collaboration: This session, led by Feedzai, will explore the critical role of banks in preventing scams.Day 2 will shift to specific industries and technologies most at risk:Financial Services: Featuring industry leaders like Capital One and Mastercard, this session will explore how multi-sector collaboration can build the perfect anti-fraud infrastructure.Telecom: Focuses on how telecom companies can improve security to protect consumers.Customer Digital Experience: Major platforms like Amazon will discuss how to strengthen protections at key digital touchpoints.Blockchain: Investigating scams in crypto and blockchain, chaired by Cube3.AI.Cybersecurity: Trend Micro will lead panels on advanced investigation techniques, focusing on scams like sextortion and pig butchering.Uniting Expertise for a Scam-Free Future"Consumers globally are facing a crisis with scams. Governments, private industry, and law enforcement must come together and act now," says Jorij Abraham, Managing Director of GASA. "Our aim at this summit is not only to discuss the problems but to build solutions that protect consumers worldwide."Confirmed Speakers:Glen Prichard, UNODCJean-Jacques Sahel, GoogleMatthew Noyes, U.S. Secret ServiceLaura Quevedo, MastercardBen Chance, ZelleAmy Nofziger, AARPMauro Ellovitch, MPMGThe summit will also launch the annual Global State of Scams Report 2024, offering an in-depth analysis of major scam trends and their impact.Join us in Washington, D.C., for this landmark event. Visit gasa.org/gass-2024-americas to view the full schedule and register.Contact InformationSam RogersMarketing Director, Global Anti-Scam Alliancesam.rogers@gasa.orgSOURCE: Global Anti-Scam Alliance (GASA) Copyright 2024 ACN Newswire via SeaPRwire.com.

Vyasa Yoga SG Marks Silver Jubilee with International Wellness Conference

SINGAPORE, Oct 25, 2024 - (ACN Newswire via SeaPRwire.com) - Vyasa Yoga SG, Singapore’s leading yoga institute, proudly celebrated its Silver Jubilee this month, marking 25 years of transforming lives through yoga and holistic health practices. Founded with S-VYASA, Vyasa Yoga SG has empowered thousands through its scientific, research-based yoga training and therapy programs, building a community of 3,000 certified yoga instructors and 500 yogi health therapists.The Silver Jubilee celebrations were inaugurated by esteemed guests, including Deputy High Commissioner of India Pooja Tillu, Neil Parekh, Chairman of Singapore Indian Chamber of Commerce and Industry (SICCI), Dr. H R Nagendra Guruji, Padma Shri awardee and renowned yoga guru, and Dr. Manjunath NK, Vice-President of the Asian Yoga Therapy Association, alongside Vyasa Yoga SG Founder, Manoj Thakur.To commemorate the milestone, Vyasa Yoga SG hosted the **International Conference on "Comprehensive Wellness Strategy" from October 19th to 20th, 2024 at the Galaxy Ballroom, CSC Tessensohn Club. The conference brought together 50 experts from 11 countries to explore integrating ancient yoga wisdom with modern science to enhance well-being. In her keynote address, Deputy High Commissioner Pooja Tillu emphasized the global relevance of yoga, stating: “Continue embracing yoga practice as a guiding light that will bring us together as a global family.”Manoj Thakur, Founder of Vyasa Yoga SG, reflected on the institute’s journey, “It has been a remarkable 25-year journey. Our success reflects the spirit of well-being we have cultivated in Singapore and beyond. We look forward to guiding people towards healthier, happier lives for many more years to come.”The event featured live yoga demonstrations and a special recognition ceremony to honor the institute’s significant contributions to health and wellness in Singapore. Vyasa Yoga SG is planning a series of events throughout the year to celebrate its 25th anniversary.About Vyasa Yoga SGEstablished to promote a healthy lifestyle through a scientific approach to yoga, Vyasa Yoga SG offers a variety of accredited programs for all ages and levels. With a mission to foster a culture of well-being, the institute continues to be at the forefront of holistic health in Singapore. For more information, visit  https://vyasasingapore.com/. For further media queries contact:Ganesh Somwanshiganesh@mettai.world Copyright 2024 ACN Newswire via SeaPRwire.com.

Everest Medicines Announces the Launch of VELSIPITY(R) in the Guangdong-Hong Kong-Macau Greater Bay Area

SHANGHAI, Oct 25, 2024 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK, “Everest”, or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that, through the "Hong Kong and Macau Medicine and Equipment Connect" policy, VELSIPITY(R) has officially been approved for patients with moderately to severely active ulcerative colitis (UC) by the Guangdong Provincial Medical Products Administration and can first be used in the Foshan Fosun Chancheng Hospital and the First Affiliated Hospital of Sun Yat-sen University, two of the medical institutions designated by the "Hong Kong and Macau Medicine and Equipment Connect" policy in the Greater Bay Area. Subsequently, VELSIPITY(R) will be introduced in other qualified hospitals under the connect policy. VELSIPITY(R) is now the third commercialized product of Everest Medicines.VELSIPITY(R) is an innovative advanced therapy that was officially approved by the Pharmaceutical Administration Bureau of Macau in April 2024. It is an oral treatment taken once daily for the treatment of patients aged 16 and above with moderately to severely active UC. UC is a chronic, relapsing, non-specific inflammatory disease, and as the disease progresses, the risk of disability and colorectal cancer incidence continues to rise. By 2030, the number of patients with UC in China is expected to more than double compared to 2019, reaching approximately 1 million, with a significant unmet need for innovative therapies.“The launch of VELSIPITY(R) in the Greater Bay Area accelerates the access to this advanced therapy in mainland China, offering a new option for patients with moderately to severely active UC." Said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “Everest Medicines is committed to expeditiously delivering innovative therapies to patients. Moving forward, we will keep leveraging our strengths and exploring innovative ways to improve the accessibility of these therapies. We plan to have VELSIPITY(R) submitted for new drug application in mainland China by the end of this year, further enhancing its accessibility and benefiting more patients." VELSIPITY(R) was developed by Arena Pharmaceuticals, which was acquired by Pfizer in 2022. Everest Medicines obtained exclusive rights to develop, produce, and commercialize VELSIPITY(R) in Greater China and South Korea from Arena as early as 2017. As a core product in the field of autoimmune diseases for Everest Medicines, VELSIPITY(R) was successively approved in Macau and Singapore in the first half of this year and was approved in the United States and the European Union in October last year and February this year, respectively. In addition, Everest Medicines recently submitted an new drug application for VELSIPITY(R) in Hong Kong, China.VELSIPITY(R) is the first and only advanced oral UC therapy approved for use in patients 16 years of age or older in the EU, and the ELEVATE UC 52 and ELEVATE UC 12 were the only studies of advanced therapies for UC to include patients with isolated proctitis. In the results of the Asian multi-center Phase 3 clinical trial of VELSIPITY(R) for the treatment of moderately to severely active UC announced in July this year, VELSIPITY(R) achieved positive topline data results in both the induction and maintenance treatment periods, with good safety profile, and is convenient to take once a day, providing further solid scientific basis and support for the wide application of the drug in clinical practice.About VELSIPITY(R) (etrasimod)VELSIPITY(R) is a once-daily, oral, sphingosine 1-phosphate (S1P) receptor modulator that selectively binds with S1P receptor subtypes 1, 4, and 5. Regulatory approvals have been granted in US, EU, Canada, Australia, Singapore, UK, Switzerland, Israel and Macau for VELSIPITY(R) in ulcerative colitis.About Everest MedicinesEverest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company’s core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders. For more information, please visit its website at www.everestmedicines.com.Forward-Looking Statements:This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law. Copyright 2024 ACN Newswire via SeaPRwire.com.

洛杉矶时报编辑因支持哈里斯被阻止而辞职

(SeaPRwire) -   洛杉矶时报编辑Mariel Garza声称,该报拒绝支持民主党总统候选人可能会让人觉得“性别歧视和种族歧视”。 洛杉矶时报社论主管Mariel Garza在该报所有者否决编辑委员会支持副总统卡玛拉·哈里斯的计划后辞职。这位记者解释说,她对该报在“危险时期”选择保持沉默“无法接受”。 迄今为止,洛杉矶时报自2008年巴拉克·奥巴马竞选以来一直支持民主党总统候选人。然而,在其上周发布的2024年选举投票建议中,该报没有提及总统候选人,只写道今年的投票是“几代人以来最重要的选举”。 与此同时,该报支持了20多位主要来自民主党的候选人,从学校董事会到美国参议员都有。 Semafor新闻机构后来报道称,洛杉矶时报编辑委员会原本计划支持哈里斯,直到执行编辑特里·唐介入并下令不发表支持声明。据称,这一决定直接来自该报的所有者兼执行主席帕特里克·孙·雄。 这位亿万富翁周四在X上的一篇文章中解释了今年决定不支持总统候选人的原因,他说编辑委员会拒绝提供对两位候选人的非党派分析。 “编辑委员会有机会起草一份对两位候选人任期期间在白宫的所有正面和负面政策的客观分析,以及这些政策如何影响国家,”孙·雄写道。“编辑委员会没有像建议的那样采取这条道路,而是选择保持沉默,我接受了他们的决定,”他说。 在哥伦比亚新闻评论发表的辞职信中,加尔萨辩称,阻止编辑委员会支持哈里斯的做法让该报“看起来怯懦和虚伪,甚至可能有点性别歧视和种族歧视。” “我们怎么能花八年时间抨击[前总统唐纳德]特朗普及其领导层对国家的危险,然后又拒绝支持我们之前支持参议员提名的、完全体面的民主党挑战者呢?”她写道,并补充说,“保持沉默不仅仅是漠不关心,而是同谋。” 在洛杉矶时报没有发表总统支持声明后,特朗普竞选团队发表声明称,即使是哈里斯的“加州同胞也知道她不适合这份工作。” 本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。

Fujitsu and Toyota Systems Corporation achieve 50% reduction in core system update time using generative AI

Kawasaki and Nagoya, Japan, Oct 25, 2024 - (JCN Newswire via SeaPRwire.com) - Fujitsu Limited and Toyota Systems Corporation (Toyota Systems) today announced the successful completion of field trials leveraging Fujitsu’s generative AI offerings on Fujitsu Kozuchi (1) to improve productivity and accelerate the modernization of Toyota Systems’ system development and operations. The trials confirmed a 50% reduction in the work time required for system updates as compared to conventional manual processes. The reductions were achieved by automating incompatibility checks and removals and program correction associated with OS and programming language updates.Based on these positive results, Toyota Systems will commence practical application of this technology starting January, 2025.Toyota Systems develops and operates core systems for production, logistics, sales, and other functions used by the Toyota Group. Sometimes it is necessary to update the underlying OS and programming languages of these systems, but carrying out the associated tasks of compatibility checks, identifying affected areas, correcting programs, and conducting testing are labor-intensive.To address this challenge, Fujitsu and Toyota Systems started trials in October 2023, leveraging Toyota Systems’ expertise in core systems and Fujitsu’s software development and generative AI knowledge to find a way to streamline the updating process.The field trials focused on approximately 15,000 files developed in Java and SQLJ. The generative AI successfully extracted system-impacting incompatibilities based on provided information and automatically corrected the programs. Fujitsu and Toyota Systems confirmed the corrections were accurate and as a result achieved a 50% reduction in work time compared to if the tasks had been carried out manually.Moving forward, the two companies aim to further improve productivity by expanding the application of generative AI to other programming languages beyond Java and SQLJ, as well as to the testing phase. They also plan to deploy this technology to other Toyota Group systems and projects to accelerate modernization across the organization.Toyota Systems will leverage generative AI to radically improve system development efficiency, freeing up resources to drive further innovation and ultimately deliver new value to the mobility sector and society. Fujitsu will continue to support Toyota Systems’ initiatives and aims to commercialize an AI service that streamlines program updates, contributing to the Toyota Group's digital transformation (DX).Figure: Diagram of the update process using Fujitsu’s generative AI offerings on Fujitsu Kozuchi [1] Fujitsu’s generative AI offerings on Fujitsu Kozuchi: Interactive generative AI service for enterprises provided via Fujitsu Kozuchi through the Fujitsu Data Intelligence PaaS operations platformAbout FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers in over 100 countries, our 124,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: Computing, Networks, AI, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.7 trillion yen (US$26 billion) for the fiscal year ended March 31, 2024 and remains the top digital services company in Japan by market share. Find out more: www.fujitsu.com.About Toyota Systems CorporationToyota Systems is an IT solutions company established in Jan. 2019 by merging 3 different Toyota IT subsidiaries. The mission of the company is to support Toyota Motor Corporation and its group companies by developing innovative IT solutions and, by doing so, to contribute to develop the mobility society of the future. The number of the employees is approximately 3,000 and its support covers most of the Toyota’s main business areas such as R&D, production, logistics, sales, administration etc... For more information, please see https://www.toyotasystems.com/en/.Press Contacts:Fujitsu LimitedPublic and Investor Relations DivisionInquiriesToyota Systems CorporationPR and Management GroupInquiries Copyright 2024 JCN Newswire via SeaPRwire.com.

云顶新耀宣布伊曲莫德(VELSIPITY)获批进入粤港澳大湾区 为溃疡性结肠炎患者带来新选择

上海, 2024年10月25日 - (亚太商讯 via SeaPRwire.com) - 云顶新耀(HKEX 1952.HK)是一家专注于创新药研发、临床开发、制造和商业化的生物制药公司,今日宣布,得益于"港澳药械通"政策,伊曲莫德(VELSIPITY(R))正式获得"粤港澳大湾区内地临床急需进口港澳药品批件"批准,可以在佛山复星禅诚医院、中山大学附属第一医院两家大湾区药械通政策指定的医疗机构先行使用,后续该产品将在其他药械通资质医院陆续引入。伊曲莫德成为云顶新耀第三款商业化新药。伊曲莫德是一款创新的先进疗法,于2024年4月获得中国澳门特别行政区药物监督管理局正式批准,每日一次口服,用于治疗16岁及以上中重度活动性溃疡性结肠炎(UC)患者。溃疡性结肠炎是一种慢性、复发性、非特异性炎症性疾病,随着病情延长,致残率和结直肠癌发生率会不断上升。到2030年,中国的溃疡性结肠炎患者人数预计将比2019年增加一倍以上,达到约100万人,患者对创新疗法存在巨大未满足需求。云顶新耀首席执行官罗永庆表示:"非常高兴看到伊曲莫德正式落地粤港澳大湾区,加快了该先进疗法在中国大陆可及,为更多溃疡性结肠炎患者带来治疗新选择。云顶新耀致力于将创新疗法以最快速度带给患者,未来,我们将继续依托国家医药产业政策,发挥自身优势,不断探索创新模式来实现创新疗法的加速落地。预计下半年,我们将在中国大陆地区递交伊曲莫德的新药上市许可申请,以进一步推进伊曲莫德的用药可及性,造福更多患者。"伊曲莫德由Arena Pharmaceuticals公司开发,辉瑞于2022年完成了对Arena Pharmaceuticals的收购,而云顶新耀早在2017年已从Arena获得了在大中华区和韩国开发、生产和商业化伊曲莫德的独家权利。伊曲莫德于去年10月和今年2月先后在美国和欧盟获得新药上市批准。作为云顶新耀自身免疫性疾病领域的重磅产品,伊曲莫德亦于今年上半年陆续在中国澳门、新加坡获得新药上市批准。此外,云顶新耀也于近期在中国香港递交了伊曲莫德的新药上市许可申请。伊曲莫德是欧盟首个且唯一获批用于16岁及以上患者的新一代口服治疗溃疡性结肠炎药物,也是目前唯一在全球Ⅲ期临床试验中证实对孤立性直肠炎有疗效的药物。在今年7月公布的伊曲莫德治疗中重度活动性溃疡性结肠炎的亚洲多中心Ⅲ期临床研究结果中,伊曲莫德取得了在诱导期和维持期治疗的积极结果,且安全性良好,一天一次口服方便,为该药物在临床实践中的广泛应用进一步提供了坚实的科学依据和支持。关于伊曲莫德(VELSIPITY(R), etrasimod)伊曲莫德(VELSIPITY(R),etrasimod)是一种每日一次口服的高选择性鞘氨醇-1-磷酸(S1P)受体调节剂,采用优化的药理学设计,与S1P受体1、4和5结合。伊曲莫德目前已在美国、欧盟、加拿大、澳大利亚、英国、瑞士、以色列以及中国澳门和新加坡获得新药上市批准。关于云顶新耀云顶新耀是一家专注于创新药研发、临床开发、制造和商业化的生物制药公司,致力于满足亚洲市场尚未满足的医疗需求。云顶新耀的管理团队在中国及全球领先制药企业从事过高质量研发、临床开发、药政事务、化学制造与控制(CMC)、业务发展和商业化运营,拥有深厚的专长和丰富的经验。云顶新耀已打造多款疾病首创或者同类最佳的药物组合,公司的治疗领域包括肾科疾病、感染性和传染性疾病、自身免疫性疾病。有关更多信息,请访问公司网站:www.everestmedicines.com。前瞻性声明本新闻稿所发布的信息中可能会包含某些前瞻性表述,乃基于本公司或管理层在做出表述时对公司业务运营情况及财务状况的现有看法、相信、和现有预期,可能会使用"将"、"预期"、"预测"、"期望"、"打算"、"计划"、"相信"、"预估"、"确信"及其他类似词语进行表述。这些前瞻性表述并非对未来业绩的保证,会受到风险、不确定性及其他因素的影响,有些乃超出本公司的控制范围,难以预计。因此,受我们的业务、竞争环境、政治、经济、法律和社会情况的未来变化及发展等各种因素及假设的影响,实际结果可能会与前瞻性表述所含资料有较大差别。本公司及各附属公司、各位董事、管理人员、顾问及代理未曾且概不承担更新该稿件所载前瞻性表述以反映在本新闻稿发布日后最新信息、未来项目或情形的任何义务,除非法律要求。 Copyright 2024 亚太商讯 via SeaPRwire.com.

Founder of Hua Medicine Dr. Chen Li was awarded the ‘C.C. Tan Life Science Industrialization Award’

HONG KONG, Oct 25, 2024 - (ACN Newswire via SeaPRwire.com) -  The 17th “C.C. Tan Life Science Award” ceremony was held at Shenyang Pharmaceutical University on October 9th. Dr. Chen Li, Founder and Chief Executive Officer of Hua Medicine, was awarded the “C.C. Tan Life Science Industrialization Award”. C.C. Tan Life Science Award has the highest honor as “the Chinese Nobel” in life science. In the context of the comprehensive construction of Chinese-style modernization and the development of new productivity, this award is a high recognition of Dr. Chen Li's outstanding contributions to the industrialization of life science achievements, and a full affirmation of his decades-long efforts to promote conceptual, technological and institutional innovations in biopharmaceutical industry.Dr. Chen Li participated in the award ceremony and received the “C.C. TanLife Science Industrialization Award”.“C.C. Tan Life Science Award” was proposed by Mr. Tan Jiazhen, one of the founders of modern genetics in China and an outstanding scientist and educator in modern China, which was approved by the Ministry of Science and Technology of the People's Republic of China, aims to promote the industrialization of China's life sciences research results and stimulate life scientists to make innovations. Since its establishment in 2008, C.C. Tan Life Science Award has been awarded annually to scientists, professors and young scholars who have made achievements in life science in the People's Republic of China and have made outstanding contributions to the industrialization of scientific and technological achievements in life science.With more than 30 years of experience in new drug R&D and management, Dr. Chen Li returned to Shanghai from the U.S. in 2004, and participated in the establishment of Roche R&D Center, the first R&D center of a multinational company in Shanghai, bringing the advanced experience, talent concept, technical standards and quality management system of international new drug R&D to China, and contributing to the establishment of the environment of China's biopharmaceutical industry. Dr. Chen Li has contributed to the establishment of China's biopharmaceutical industry environment.In 2010, Dr. Chen Li founded Hua Medicine in Zhangjiang, Shanghai, with the original intention of “China leads the way in pharmaceutical innovation”, adhering to the tenet of “patients first, innovation first, and good medicines for the people”, focusing on the unmet clinical needs, and concentrating on the research and development of first-of-its-kind new medicines for diabetes. Dr. Chen Li is not only one of the earliest pioneers to leave his executive position at a multinational pharmaceutical company to start a local innovative drug company, but also a leader in developing First-in-Class drugs in China.In September 2022, under the leadership of Dr. Chen Li, Hua Medicine's world's first, China's first, Class I National New Drug, Dorzagliatin (trade name: HuaTangNing®), which took ten years to develop independently, received marketing approval from the State Food and Drug Administration (SFDA), making it the first Glucose Kinesin Activator (GKA) approved and marketed globally, and the tenth class of diabetes therapeutic drugs.As the world's first GKA drug, Dorzagliatin utilizes the new concept of “repairing sensing, reshaping homeostasis, and treating diabetes at the source” to achieve the improvement of blood glucose homeostasis dysregulation in patients with type 2 diabetes mellitus, and to bring a brand-new treatment for diabetes mellitus patients, which is a major breakthrough in the history of drug research and development of China in the field of major chronic diseases.  During the development of Hua Medicine, Dr. Chen Li has actively contributed to the development of China's biopharmaceutical industry. He has provided constructive opinions and suggestions for the system of marketing license holders and the system of patent linkage and patent protection, etc. He has cooperated with enterprises in the industry chain in the R&D and production of dorzagliatin to establish a joint innovation model, which has led to the development of the ecological development of the biopharmaceutical industry. In early 2024, Dr. Chen Li was awarded the first “Shanghai Outstanding Talent”. He is also the inventor of 119 granted invention patents and 270 invention patent applications and has been published more than 70 scientific papers in Nature Medicine, Lancet Diabetes Endocrinology, Nature Communication, PNAS, Diabetes, Obesity Metabolism, and the Journal of Biomedicine. PNAS, Diabetes, Obesity Metabolism, JACS, JOC and other international academic journals.About Hua MedicineHua Medicine is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin on hydrochloride-tolerated T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with varying degrees of renal function impairment (including end-stage renal impairment without dialysis). Hua Medicine partnered with Bayer, a leading global pharmaceutical company, to commercialize HuaTangNing in China, benefiting diabetic patients and their families.For more informationHua MedicineWebsite:  www.huamedicine.comInvestorsE-mail: ir@huamedicine.comMediaE-mail: pr@huamedicine.com Copyright 2024 ACN Newswire via SeaPRwire.com.

DIFC continues to drive global action in shaping greener economies – Announces 2nd edition of the Future Sustainability Forum in Dubai

DUBAI, Oct 25, 2024 - (ACN Newswire via SeaPRwire.com) - Dubai International Financial Centre (DIFC), the leading global financial hub in the Middle East, Africa and South Asia (MEASA) region, announces the 2nd edition of the Future Sustainability Forum. Scheduled for 4 and 5 December 2024 at the Madinat Jumeirah, Dubai, the Forum will focus on mobilising sustainable practices, engaging in influential discussions on sustainable development, working towards environmental conservation, social equity and innovation.The announcement of the 2nd edition of the Forum underscores DIFC’s commitment to advancing UAE sustainability priorities alongside initiatives such as the DIFC Sustainable Finance Catalyst which aims to grow sustainable finance flows from Dubai to USD 100+ billion by 2030.The Forum coincides with the first anniversary of COP28 being hosted in the UAE and is set to attract over 3,000 participants. The event will mobilise industry leaders, investors, tech disruptors, and policymakers into achieving the United Nations Sustainable Development Goals (SDGs) and contributing to the delivery of the Paris Agreement, whilst aiming to channel investment flows between the global north and south to accelerate climate action.Alya Al Zarouni, Chief Operating Officer of DIFC Authority and Co-Chair of the Dubai Sustainable Finance Working Group, said, “The DIFC organised Future Sustainability Forum is a vital platform for collaborative action towards a more sustainable future. As the global economic landscape evolves, so must our commitment to responsible and inclusive growth. At DIFC, we are proud to be convening this gathering of industry leaders, innovators, and policymakers to address the most pressing environmental and social challenges of our time. Together, we can forge new pathways to a more resilient and sustainable future for financial services and other important industries.”Dr Bernd van Linder, Chief Executive Officer of the Commercial Bank of Dubai, the presenting sponsor of the Forum, stated, "Commercial Bank of Dubai is proud to support the UAE's sustainability ambitions through our participation in the Future Sustainability Forum 2024 as Presenting Sponsor. Our proactive approach in addressing environmental challenges, exemplified by the successful issuance of CBD's inaugural green bond, demonstrates our alignment with global environmental goals."The Forum will address critical sustainability issues across eight core pillars spanning different industries including banking and finance, construction, renewable and future energy, transportation and mobility, manufacturing and production, recycling and waste management, sustainable technology, and agriculture and food production.In addition to the packed conference agenda that will feature over 100 sustainability and climate action expert speakers, the Forum will bring together the most innovative solutions and service providers from across the global sustainability landscape through the Climate Action & Renewable Energy Expo (CARE).Government entities in the UAE have spearheaded a range of comprehensive sustainability programmes in the pursuit of a net-zero future. Initiatives such as the Dubai Clean Energy Strategy 2050, the UAE Net Zero 2050 strategic initiative, and the UAE Vision 2070, emphasise on a commitment to renewable energy adoption, water conservation, waste management, and sustainable urban development.For more information and to register, please visit the Future Sustainability Forum website.About Dubai International Financial CentreDubai International Financial Centre (DIFC) is one of the world’s most advanced financial centres, and the leading financial hub for the Middle East, Africa, and South Asia (MEASA), which comprises 77 countries with an approximate population of 3.7bn and an estimated GDP of USD 10.5trn.With a 20-year track record of facilitating trade and investment flows across the MEASA region, the Centre connects these fast-growing markets with the economies of Asia, Europe, and the Americas through Dubai. DIFC is home to an internationally recognised, independent regulator and a proven judicial system with an English common law framework, as well as the region’s largest financial ecosystem of 43,800 professionals working across over 6,150 active registered companies – making up the largest and most diverse pool of industry talent in the region. The Centre’s vision is to drive the future of finance through cutting-edge technology, innovation, and partnerships. Today, it is the global future of finance and innovation hub offering one of the region’s most comprehensive FinTech and venture capital environments, including cost-effective licensing solutions, fit-for-purpose regulation, innovative accelerator programmes, and funding for growth-stage start-ups.  Comprising a variety of world-renowned retail and dining venues, a dynamic art and culture scene, residential apartments, hotels, and public spaces, DIFC continues to be one of Dubai’s most sought-after business and lifestyle destinations. For further information, please visit our website: difc.ae, or follow us on LinkedIn and X @DIFC.For media enquiries, please contact:Nivine William | Nisha CelinaBurson | bursonglobal.comnivine.william@bursonglobal.com | nisha.celina@bursonglobal.com Rasha Mezher | Dubai International Financial Centre Authority Manager, Marketing & Corporate CommunicationsRasha.Mezher@difc.ae Hussain AlZaabi | Dubai International Financial Centre AuthorityManager, DIFC Innovation Hubhussain.alzaabi@difc.ae Shadi DawiDirector - PR & Media+971 55 498 4989shadi@tresconglobal.com  Copyright 2024 ACN Newswire via SeaPRwire.com.

HighTide Therapeutics to Present Analyses of Phase 2 MASH Study at AASLD’s The Liver Meeting 2024

HONG KONG, Oct 25, 2024 - (ACN Newswire via SeaPRwire.com) - HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for chronic liver and metabolic diseases, will present at the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting®, taking place from November 15-19, 2024 in San Diego, California. The presentations include post-hoc analyses of the Phase 2a clinical study of berberine ursodeoxycholate (HTD1801), a gut-liver anti-inflammatory metabolic modulator, in patients with metabolic dysfunction-associated steatohepatitis (MASH) and comorbid type 2 diabetes mellitus (T2DM) (NCT03656744).“These data provide additional characterization of the efficacy and safety of HTD1801, a novel, multifunctional therapy being developed for the treatment of patients with MASH and T2DM. If further studies confirm these findings, HTD1801 could potentially offer a more effective solution for patients who do not respond adequately to GLP-1 receptor agonists.  In addition, the observations of improved GI tolerance over time suggests that HTD1801 may be an attractive option for long-term management of chronic conditions such as MASH and T2DM. The ongoing Phase 2b study (CENTRICITY, NCT05623189), fully enrolled in 1Q 2024, evaluates the histological benefit of HTD1801 in patients with MASH and T2DM. We look forward to announcing the CENTRICITY results which we expect in the first half of 2025,” said Dr. Leigh MacConell, Chief Development Officer of HighTide.“Efficacy of Berberine Ursodeoxycholate (HTD1801) Compared to Ongoing Use of GLP-1 Receptor Agonists in Patients with MASH and T2DM” (Abstract 3218, Poster Presented November 17th)About the Abstract: As GLP-1 Receptor Agonists (GLP-1RAs) are prominently used in patients with T2DM and gaining attention as a potential treatment for MASH, this post-hoc comparative efficacy analysis evaluated ongoing GLP-1RA use compared to newly initiated HTD1801 treatment. This analysis suggests that HTD1801 provides greater improvements in markers of liver injury and inflammation, glycemic control, weight loss, and lipid metabolism compared to ongoing GLP-1RA use. These findings are important as they suggest that HTD1801 could provide additional benefit to patients with MASH and T2DM, on concomitant GLP-1RA treatment.“Time Course of Onset, Incidence, and Prevalence of Gastrointestinal Adverse Events with HTD1801 (Berberine Ursodeoxycholate) in Patients with MASH and T2DM” (Abstract 3219, Poster Presented November 17th)About the Abstract: Across several indications, the most commonly occurring adverse events (AEs) in studies of HTD1801 have been mild to moderate gastrointestinal (GI) AEs, primarily diarrhea and nausea. The purpose of this post-hoc analysis was to characterize the time course and severity of GI AEs in patients with MASH and T2DM treated with HTD1801 for 18 weeks. Based on this analysis, the incidence of GI-related AEs peaks within the first 4 weeks of treatment, was mild to moderate in severity, and importantly, showed a decreasing incidence and prevalence over the course of treatment. These data demonstrate that HTD1801 is generally well-tolerated and with continued treatment, GI tolerance improves supporting its potential long-term use in chronic diseases, such as MASH.About HighTide TherapeuticsHighTide Therapeutics, Inc. (2511.HK) is a globally integrated biopharmaceutical company focusing on the discovery and development of first-in-class multifunctional multi-targeted therapies with chronic liver and metabolic diseases with significant unmet medical needs. The company is developing multiple clinical assets, including therapy for metabolic dysfunction-associated steatohepatitis (MASH), type 2 diabetes (T2DM), severe hypertriglyceridemia (SHTG), and primary sclerosing cholangitis (PSC). Berberine ursodeoxycholate (HTD1801), the company’s lead drug candidate, received Fast Track designation from the U.S. FDA for both MASH and PSC, as well as Orphan Drug designation for PSC. In China, HTD1801 has been included in the National Major New Drug Innovation Program under the 13th Five-Year Plan for Major Technology Project.For more information, please visit www.hightidetx.com Copyright 2024 ACN Newswire via SeaPRwire.com.

君联投资企业地平线在香港联交所成功上市

香港, 2024年10月25日 - (亚太商讯 via SeaPRwire.com) - 据君联资本微信公号报道称,10月24日,联想控股(3396.HK)旗下君联资本所投智驾科技企业地平线(9660.HK)在香港联交所成功上市,地平线拟全球发行1,355,106,600股股份,其中香港公开发售135,511,200股,占约10%;国际配售1,219,595,400股,占约90%,另有超额配股权15%。截至发稿,地平线每股5.45港元,上市首日上涨36.59%,市值超过710亿港元。这标志著地平线作为一家智能驾驶解决方案的链主型领军企业,开启了全新"征程"。地平线是市场领先的乘用车高级辅助驾驶(ADAS)和高阶智能驾驶(AD)解决方案供应商,成立于2015年7月,创始人余凯博士,本硕毕业于南京大学电子科学与工程学系,长期在计算机工程领域深耕。地平线的产品包括征程系列芯片,这些芯片被广泛应用于智能驾驶领域,包括高级辅助驾驶(ADAS)和高阶智能驾驶(AD)解决方案。依托已大规模部署的前装量产解决方案,地平线已成为智能汽车转型及商业化的关键推动者。灼识咨询报告显示,自2021年起,按解决方案总装机量计算,地平线是首家且每年均为最大的提供前装量产的高级辅助驾驶和高阶智能驾驶解决方案的中国公司。地平线拥有庞大的全球客户群,包括行业领先的OEM(原始设备制造商)和国产汽车制造一级供应商,公司提供的解决方案整合了算法、专用软件和处理硬件,旨在提高驾驶安全性和乘客体验。截至2024年9月底,地平线累计定点车型290款、累计量产车型152款。目前,地平线征程家族车载智能计算方案出货量累计已突破600万套。2024年上半年,地平线营业收入9.3亿元,同比增长超150%。君联资本于2021年3月投资地平线,投资时地平线生产的智能驾驶芯片在各车企刚刚开始投入应用,投资后,公司产品持续迭代,研发生产了国内首款可量产的百TOPs级车载大算力智能驾驶芯片-征程5系列产品并形成批量生产应用,公司最新研发的征程6也持续量产并在各大车企销售。君联一路陪伴公司成长,在智能驾驶产业链上下游资源引荐等方面给予了公司支持和帮助。君联资本对地平线成功上市表示祝贺,随著汽车"智能化、网联化"的驱动,智能驾驶芯片已成为智能汽车智能驾驶的核心,地平线是行业内稀缺的有能力将算力在芯片产品上落地的企业,余凯博士带领的团队具有远大格局和前瞻性,有较强的商业落地能力和丰富的企业管理经验,随著我国智能汽车行业的持续增长,君联资本相信,上市后的地平线在智能驾驶领域将会持续拓展更广阔的市场和业务链条。智能驾驶技术是新质生产力的典型代表。君联长期实践科创投资,在人工智能、碳中和、半导体、数字经济、生物医药等国家战略性产业上密集投资,深入理解和融入国家创新型企业培育体系,持续推动所投企业面向解决"卡脖子"问题的重大创新方向,补链强链。君联资本作为联控旗下专注于早期创业投资以及成长期私募股权投资的专业投资机构,在二十多年的发展历程中,遵循国际通行标准,经历了多支基金的完整管理周期,创造了可持续的基金业绩。据其官网显示,已累计投资600多家企业,其中有113家在全球不同资本市场IPO退出,近100家通过并购退出。其所投企业中,既包括科大讯飞、宁德时代、药明康得、康龙化成这样的顶尖企业,也有大量的国家级专精特新小巨人和制造业单项冠军,构建了丰富的产业资源。 Copyright 2024 亚太商讯 via SeaPRwire.com.

侨雄国际否认媒体操纵股价质疑 称价格波动是市场对公司未来预期反应

香港, 2024年10月25日 - (亚太商讯 via SeaPRwire.com) - 针对公司近日股价持续上涨,引发媒体质疑涉嫌操纵股价的报导、侨雄国际(00381.HK)今日盘后发布公告称,经公司董事会作出一切合理查询后所知、所悉及所信,董事会坚决否认媒体报导中包含的猜测,并认为报导事项不准确且具有误导性。侨雄国际在公告中进一步指出,公司已经谘询其法律顾问,将会作出进一步行动。此外公司向负责传播误导性及恶意陈述,恶意沽空从而获益的有关实体及╱或相关个人及任何人,导致的损害或其他补偿,保留采取法律行动之权利。10月22日,有媒体发布题为《16个交易日翻了近30倍,侨雄国际(00381)全靠两个"经纪商"雄起?》,指出截至10月21日,中国北方证券和长桥证券两个经纪商近20个交易日分别净买入了0.92亿股和0.27亿股,持股比例分别为14.02%及3.42%,而其他经纪商仅有少量买入,由此质疑公司股价存在被操纵的嫌疑。侨雄国际执行董事兼联席主席李立中对媒体回应称,价格的波动是市场对公司未来预期的反应,是正常的市场行为。首先,乘著近期港股的升浪,很多公司股票都有明显的升幅。加上公司近来管理层的变动,委任了有丰富资历以及管理经验的董事,这些可被股东看作利好消息,公司股价上涨表示股东对公司前景乐观。二零二四年十月四日,侨雄国际委任李立中为执行董事兼联席主席。李立中长期从事人工智慧、元宇宙、智联网路、区块链科学研究,这些领域的研究成果不仅推动了科技进步,而且为人类的生活带来了巨大的改变。其工作成果向世界展示了中国科学家的智慧和实力,也为中国在科技领域的发展做出了重要贡献。侨雄国际表示,国家"十四五"规划中提出迎接数字时代,启动数据要素潜能,推进网络强国建设,加快建设数字经济、数字社会、数字政府,以数字化转型整体驱动生产方式、生活方式和治理方式变革。基于"十四五"规划所带来的数字化新浪潮,各行各业将获得更多发展机遇,面对中国社会经济发展新阶段、新特征,公司未来将专注于深化现有业务开发及运营,向数字媒体经销等方向稳定发展,丰富业务的多元化结构,使得公司更加稳步向前。侨雄国际在公告中表示,董事会经作出在相关情况下有关公司的合理查询后,董事会确认,其并不知悉导致价格或成交量波动的任何原因,或任何必须公布以避免公司证券出现虚假市场的资料。李立中强调,该报导仅凭市场交易券商名字片面的指责怀疑公司操纵市场,期间并未与上市公司做任何的沟通与确认,是典型恶意沽空的犯罪行为。公司会对其新闻前恶意做空行为和新闻后操纵市场行为发出律师函和诉讼,以维护广大投资者权益。前述媒体报导称,"侨雄国际基本面并不好,公司主要从事玩具及礼品制造及销售、天然资源勘探、水 果种植、休闲及文化及中草药多种业务,业务表现平淡,业绩收入已经连续两个半年度下行,且盈利能力持续下降。今年该公司业务模式并未有重大变化,唯一变化是在10月10日,拟将公司名称更名为权识国际集团(中文名称)。"侨雄国际近期发布公告,拟将公司名称更改为"AOM International Group Company Limited",并采用"权识国际集团股份有限公司"作为其第二中文名称。据悉,集团的业务有六大可呈报分类,由于各业务均有不同的经济特征,因此各业务被分开管理。对此李立中表示,侨雄国际更名为权识国际。未来会通过相关专利技术对公司各板块业务做全方位的数位经济转型,通过生产资料的标识化,为公司的各个板块注入新的价值与活力。因此引发股价上涨和投资者购买属于正常市场现象。李立中指出,目前侨雄国际的资金状况非常健康,公司管理层对公司发展的前景保持绝对的乐观态度,会考虑在未来继续增持公司股票,以带给市场及公司股东信心,稳定因为不实报道,故意抹黑而影响的公司股价。关于后续的业务安排,公司会按照上市公司管理要求走合规的业务流程正常公告披露。公司谨提醒公司股东及潜在投资者,关注公司于联交所网站(http://www.hkexnews.hk/index.htm) 。 Copyright 2024 亚太商讯 via SeaPRwire.com.

以色列军方要求阵亡士兵家属移除墓碑上的十字架

(SeaPRwire) -   官员表示,在公墓中展示该符号是对附近安葬的犹太士兵亲属的冒犯。 以色列国防军(IDF)威胁要重新安葬一名阵亡的基督教士兵,除非他的家人同意从他的墓碑上移除十字架,这名士兵的亲属告诉当地媒体。大卫·博格达诺夫斯基于 2014 年从乌克兰移居以色列,去年 12 月在加沙地带被反坦克火箭杀害。 博格达诺夫斯基的家人周一告诉媒体,他们收到了国防部的信函,要求他们移除十字架,否则将把这名中士的遗骸重新安葬在海法军人公墓之外。 “根据法律,不允许在军人墓碑上放置十字架或任何其他宗教标记,”国防部表示。据报道,这封信援引了以色列国防军首席拉比的一项裁决,该裁决称十字架的存在亵渎了犹太公墓的圣洁。 据报道,军方官员还声称,他们收到了“埋葬在附近的亲人[和]声称十字架伤害了他们的感情和祈祷能力”的家庭的投诉。 博格达诺夫斯基的母亲告诉 Ynet,她本月早些时候去探望她儿子的坟墓时,发现他的墓碑上盖着黑布。 “我无言以表我所感受到的耻辱,”这名妇女告诉记者。 “我认为我的大卫,他为这个国家献出了生命,他全心全意地爱着这个国家……与其他任何士兵没有什么不同,[而且]不是二等公民。我站在那里哭泣,感到愤怒、沮丧和难以置信,”她说。 这位士兵的母亲在 Facebook 上的一篇文章中解释说,她已故儿子的信仰是他身份的“不可分割的一部分”。她还对儿子被单独挑出来表示震惊,并指出公墓中还有其他带有十字架的墓碑。 虽然以色列的公墓通常按宗教划分,但一项特殊法律允许非犹太裔军人与他们的犹太裔战友一起埋葬在军人公墓。 2023 年底,以色列中央统计局估计,基督教徒占人口的 1.9%。 2023 年 10 月,哈马斯武装分子对以色列领土发动了致命袭击,造成约 1100 人死亡,并劫持了 200 多名人质,以色列发起了对加沙的军事行动。根据巴勒斯坦飞地的卫生部门的数据,一年的重度以色列空袭和地面进攻已造成近 42,000 人在加沙死亡。 本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。

西方制裁阻碍气候研究 – NYT

(SeaPRwire) -   据该报报道,欧盟和美国的科学家无法使用来自俄罗斯的关键数据。 据《纽约时报》报道,西方对俄罗斯的制裁阻碍了对气候变化至关重要的研究,俄罗斯掌握着关于北极的关键数据。   自2022年2月乌克兰冲突升级以及随后西方对莫斯科实施制裁以来,美国和欧洲科学家被告知停止与俄罗斯同行合作,该报周二报道。 《纽约时报》报道称,此举令西方科学家争先恐后地寻找关键数据,因为俄罗斯在北极海岸线和陆地面积方面占了超过一半。 监测该地区的温度是气候变化研究和建模的核心,因为冰川融化会导致海平面上升,以及温度和降水模式发生变化。 “没有俄罗斯,可能无法了解北极的变化方式,”该报援引意大利多年冻土科学家亚历山德罗·隆吉的话说。 据丹麦国际研究所称,俄罗斯被排除在外意味着“目前缺少一半的北极气候数据集”。 在乌克兰冲突爆发后,大多数欧盟和北约成员国决定暂停所有涉及俄罗斯机构或在俄罗斯进行的研究项目。 俄罗斯野外考察站被从国际陆地研究和监测北极网络中移除,该网络是北纬地区 60 个野外考察站的全球网络。今年早些时候发表在英国科学杂志《自然》上的一项研究指出,这导致了用于监测生态系统变化的数据“明显”丢失。 然而,北极的科学联系正在发生变化,俄罗斯国际事务委员会今年早些时候表示,新的伙伴关系,特别是与中国和印度的伙伴关系正在形成。   据俄罗斯日报《独立报》此前报道,金砖国家和上海合作组织以及拉丁美洲、中东和亚太地区的国家已表达了对北极的兴趣。   该报指出,中国和印度已从北极理事会(一个促进北极国家之间合作的政府间论坛)的观察员转变为积极参与北极研究项目。 本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。

切斯特金融财富管理:您在切斯特值得信赖的独立理财顾问

(SeaPRwire) -   Chester Financial Wealth Management 为切斯特提供专业的独立财务咨询服务,为切斯特的退休、投资和财富保护提供量身定制的解决方案。 Cheadle Hulme, Cheshire 2024 年 10 月 24 日 - Chester Financial Wealth Management 自豪地为切斯特社区服务,为个人、小型企业主和受托人提供高质量的独立财务咨询。作为一家家族企业,我们植根于当地,提供以信任、诚信和公平为基础的个性化服务。提供高质量的独立财务咨询在 Chester Financial Wealth Management,我们致力于指导客户完成各种财务规划需求。我们的综合服务包括在退休规划、投资策略、财富保护和遗产税规划等领域的专业咨询。通过与客户密切合作,我们制定反映客户独特目标和担忧的长期财务策略。专业知识和职业资格Chester Financial Wealth Management 由 Mark Bird 领导,他是金融规划领域备受尊敬的人物。Mark 拥有特许财务规划师资格和特许保险协会会员资格——这些都是英国不到 30% 的金融顾问拥有的声望很高的资格。这些荣誉仅颁发给该领域最敬业的专业人士,反映了 Mark 对金融规划卓越的承诺。个性化的财务解决方案Chester Financial Wealth Management 的与众不同之处在于我们个性化的以客户为中心的理念。我们专注于与客户建立持久的关系,这种关系建立在信任和透明的基础上。通过花时间了解每个客户的财务状况,我们制定符合客户长期目标的策略。我们公司承诺每年至少与客户会面一次,以审查他们的财务计划。这种定期联系确保策略保持灵活和相关性,考虑到个人情况或财务法规的任何变化。“我们的客户欣赏我们说的是他们的语言,而不是行业术语。我们在所有事情上都提供清晰度,而不是复杂性,”Mark Bird 补充道。为什么选择 Chester Financial Wealth Management?作为一家真正的  Financial Wealth Management 并不与任何金融产品或提供商捆绑在一起。这意味着我们提供公正的、全市场的建议,确保我们推荐的解决方案符合客户的最佳利益。在一个金融格局可能快速变化的世界里,我们的客户信任我们能够掌握最新的发展趋势,从税收法到市场变化。无论您是想增加财富,保护资产还是规划退休生活,Chester Financial Wealth Management 都能提供您实现安心所需的专业建议。联系 Chester Financial Wealth Management如需了解更多信息或安排咨询,请联系 Chester Financial Wealth Management: 电话:01244 311760 办公地址:Watergate House, 85 Watergate Street, Chester, CH1 2LFChester Financial Wealth Management 是 Corbel Partners Limited 的指定代表,由金融行为监管局授权和监管。注册于英格兰和威尔士,公司编号:07469633。媒体联系方式Chester Financial Wealth Management1244311760Watergate House 85, Watergate Street Chester CH1 2LF Source :Chester Financial Wealth Management本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。